Literature DB >> 6274855

Incorporation of E-5-(2-halovinyl)-2'-deoxyuridines into deoxyribonucleic acids of herpes simplex virus type 1-infected cells.

H S Allaudeen, M S Chen, J J Lee, E De Clercq, W H Prusoff.   

Abstract

E-5-(2-Bromovinyl)-2'-deoxyuridine (BrvdUrd) and E-5-(2-iodovinyl)-2'-deoxyuridine (IvdUrd) are among the most potent and selective inhibitors of herpes simplex virus type 1 (HSV-1) replication. To elucidate the site of inhibition, we examined whether the halovinyl analogs are incorporated into DNA using two approaches. (i) In assays with purified DNA polymerases omitting dTTP from the reaction system, addition of either BrvdUTP or IvdUTP increased the polymerization reaction, indicating that these two analog triphosphates can be alternate substrates. (ii) When HSV-1-infected Vero cells were grown in the presence of either BrvdUrd or IvdUrd, there was an increase in the density of both the viral and cellular DNA. The viral DNA had 40% of its thymidine moiety substituted by IvdUrd when the concentration of [125I]IvdUrd was 24 microM (in the absence of added thymidine). At 30 microM BrvdUrd and 1 microM [2-14C]thymidine, the viral DNA had only 11% of its thymidine moiety substituted by BrvdUrd, presumably because of the presence of added thymidine. Following digestion of [125I]IvdUrd-substituted DNA with DNase 1, venom phosphodiesterase, and alkaline phosphatase, the radioactivity co-migrated with nonradioactive IvdUrd in thin layer chromatography. Under similar conditions, no detectable incorporation of either [125I]IvdUrd or BrvdUrd into mock-infected Vero cell DNA was observed. Thus, IvdUrd and BrvdUrd are incorporated into DNA of HSV-1 infected cells but not into DNA of uninfected cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6274855

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

Review 1.  Specific targets for antiviral drugs.

Authors:  E De Clercq
Journal:  Biochem J       Date:  1982-07-01       Impact factor: 3.857

2.  Selective in vitro and in vivo activities of 5-(2-haloalkyl)pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus.

Authors:  E De Clercq; B Rosenwirth
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

3.  Bromovinyldeoxyuridine and interferon treatment in ulcerative herpetic keratitis: a double masked study.

Authors:  O P van Bijsterveld; P J Meurs; E de Clercq; P C Maudgal
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

4.  Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2'-deoxyuridine in vivo.

Authors:  C Desgranges; G Razaka; F Drouillet; H Bricaud; P Herdewijn; E De Clercq
Journal:  Nucleic Acids Res       Date:  1984-02-24       Impact factor: 16.971

5.  Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on synthesis of herpes simplex virus type 1-specific polypeptides.

Authors:  S A Siegel; M J Otto; E De Clercq; W H Prusoff
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

6.  Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice.

Authors:  E de Clercq; Z X Zhang; I S Sim
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

7.  Inhibition of glycosylation of bovine herpesvirus 1 glycoproteins by the thymidine analog (E)-5-(2 Bromovinyl)-2'-deoxyuridine.

Authors:  V Misra; R C Nelson; L A Babiuk
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

8.  Inhibitory effect of E-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil on herpes simplex virus replication and DNA synthesis.

Authors:  J Descamps; R K Sehgal; E De Clercq; H S Allaudeen
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

9.  Herpes simplex virus latency in isolated human neurons.

Authors:  B Wigdahl; C A Smith; H M Traglia; F Rapp
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

10.  Oral BVDU treatment of varicella and zoster in children with cancer.

Authors:  Y Benoit; G Laureys; M J Delbeke; E De Clercq
Journal:  Eur J Pediatr       Date:  1985-01       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.